|
|
发表于 2-1-2019 07:43 AM
|
显示全部楼层
Name | PULAU MEMUTIK VENTURES SDN BHD | Address | Level 33, Tower 2, Petronas Twin Towers
Kuala Lumpur City Centre
Kuala Lumpur
50088 Wilayah Persekutuan
Malaysia. | Company No. | 887202-X | Nationality/Country of incorporation | Malaysia | Descriptions (Class) | Ordinary shares |
Details of changesNo | Date of change | No of securities | Type of Transaction | Nature of Interest | | 1 | 29 Nov 2018 | 262,246,412 | Others | Direct Interest | Name of registered holder | PULAU MEMUTIK VENTURES SDN BHD | Address of registered holder | Level 33, Tower 2, Petronas Twin Towers, Kuala Lumpur City Centre, 50088 Kuala Lumpur | Description of "Others" Type of Transaction | Exercise of Option |
Circumstances by reason of which change has occurred | Exercise of the Options granted under the Shareholders' Agreement dated 23 December 2011 entered into between IHH Healthcare Berhad ("IHH"), Integrated Healthcare Hastaneler Turkey Sdn Bhd, Bagan Lalang Ventures Sdn Bhd ("Bagan Lalang"), Mehmet Ali Aydinlar and Hatice Seher Aydinlar. Bagan Lalang has nominated Pulau Memutik Ventures Sdn Bhd, which is a wholly-owned subsidiary of Khazanah Nasional Berhad to receive the new IHH Shares. | Nature of interest | Direct Interest | Direct (units) | 3,687,623,756 | Direct (%) | 42.052 | Indirect/deemed interest (units) |
| | Indirect/deemed interest (%) |
| | Total no of securities after change | 3,687,623,756 | Date of notice | 30 Nov 2018 | Date notice received by Listed Issuer | 30 Nov 2018 |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 6-1-2019 07:30 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 8-1-2019 04:37 AM
|
显示全部楼层
IHH明年分拆印度SRL醫療上市
財經 最後更新 2018年11月26日 19时58分
http://www.orientaldaily.com.my/s/269097
（吉隆坡26日訊）IHH醫療保健集團（IHH，5225，主板保健股）計劃在2019年安排旗下的SRL醫療公司上市，並在中長期內帶領這個品牌衝出海外。SRL醫療公司目前是富通醫療子公司，持股56.6%。而IHH醫療保健剛完成收購富通。
據消息人士指出，IHH醫療保健集團將為富通醫療提供額外200億盧比（約578萬令吉）的資金。
該公司早前已為這家印度醫療集團提供400億盧比的資金，這是收購富通醫療股權的條件之一。
該公司額外注入的資金，除了用作法定公開獻購、營運資金和其他方面的需求之外，還有向私募基金收購SRL醫療的31%股權。
消息人士稱，IHH醫療保健集團將SRL醫療公司分拆上市，需要6個月到1年的時間。
至於持有SRL醫療公司股權的私募基金，也正考慮脫售股權，預期很快就能簽署協議。
IHH醫療保健集團估計以110億至120億盧比收購上述股權。不僅如此，IHH醫療保健集團希望在年杪前，完成對富通股東展開的公開獻購。之後便會專注于發展醫療和間診業務。
該名消息人士也說，IHH醫療保健公司還計劃將SRL品牌推廣至國外市場，尤其是在該公司已有立足點的東南亞市場。
儘管如此，IHH並未回應此消息。 |
|
|
|
|
|
|
|
|
|
|
|
发表于 14-1-2019 11:44 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 18-1-2019 04:21 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 2-2-2019 06:27 AM
|
显示全部楼层
Type | Announcement | Subject | OTHERS | Description | Completion of acquisition of RHT Health Trust's assets by Fortis Healthcare Limited | |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 4-3-2019 02:08 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 4-3-2019 07:05 AM
|
显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
31 Dec 2018 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 31 Dec 2018 | 31 Dec 2017 | 31 Dec 2018 | 31 Dec 2017 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 3,165,348 | 2,885,133 | 11,520,932 | 11,142,639 | | 2 | Profit/(loss) before tax | 812,878 | 102,397 | 752,470 | 1,164,453 | | 3 | Profit/(loss) for the period | 710,687 | 37,346 | 489,860 | 829,828 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 509,417 | 101,255 | 627,687 | 969,953 | | 5 | Basic earnings/(loss) per share (Subunit) | 5.78 | 0.95 | 6.54 | 11.31 | | 6 | Proposed/Declared dividend per share (Subunit) | 3.00 | 3.00 | 3.00 | 3.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 2.5100 | 2.6600
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 5-3-2019 07:08 AM
|
显示全部楼层
Type | Announcement | Subject | OTHERS | Description | First and Final Single Tier Cash Dividend for financial year ended 31 December 2018 | Pursuant to Paragraph 9.19(2) of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad, the Board of Directors ("Board") of IHH Healthcare Berhad ("IHH") is pleased to propose a first and final single tier cash dividend of 3 sen per ordinary share of IHH (“Final Dividend”) for the financial year ended 31 December 2018, subject to the shareholders' approval at the forthcoming Ninth Annual General Meeting.
The book closure and payment date in respect of the proposed Final Dividend will be determined by the Board at a later date.
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 5-3-2019 07:08 AM
|
显示全部楼层
Type | Announcement | Subject | OTHERS | Description | Revaluation of Investment Properties | |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 5-3-2019 07:30 AM
|
显示全部楼层
Date of change | 01 Mar 2019 | Name | MR MEHMET ALI AYDINLAR | Age | 62 | Gender | Male | Nationality | Turkey | Type of change | Redesignation | Previous Position | Executive Director | New Position | Non Executive Director | Directorate | Non Independent and Non Executive |
QualificationsNo | Qualifications | Major/Field of Study | Institute/University | Additional Information | | 1 | Degree | Business Administration | Galatasaray Economyand Management College | |
Working experience and occupation | Mr. Aydinlar is presently the Chairman and Chief Executive Officer of Acibadem Saglik Yatirimlari Holding A.S. ("ASYH"), a 90%-owned subsidiary of IHH. He also serves as the Chairman of the Board of the ASYH group of companies which includes A Plus, Acibadem Project Management, Acibadem Mobile Services and Acibadem Labmed. He is also the Chairman of the Turkish Accredited Hospitals Association. As of 2015, Mr. Aydinlar has been serving on the board of the Foreign Economic Relations Board. This institution is responsible for leading foreign economic relations within the Turkish private sector in a myriad of sectors, as well as for increasing export volume of Turkish businesses and coordinating similar business development activities.A certified public accountant-turned-entrepreneur, Mr. Aydinlar has been recognised for his extensive experience in management and involvement in the healthcare sector since 1993. Being a philanthropist, Mr. Aydinlar is also the Chairman of the Board of Trustees of Acibadem University, an ambitious social responsibility undertaking he initiated to advance healthcare in Turkey through education and research. | Family relationship with any director and/or major shareholder of the listed issuer | Nil | Any conflict of interests that he/she has with the listed issuer | Nil | Details of any interest in the securities of the listed issuer or its subsidiaries | Interest in the securities of IHH as at 27 February 2019: Direct Interest1) 420,244,132 ordinary shares 2) 665,000 Long Term Incentive Plan (LTIP) units3) 2,283,000 Enterprise Option Scheme (EOS) options Indirect Interest107,319,041 ordinary shares |
| Remarks : | | Mr. Aydnlar will be re-designated from Chairman and Chief Executive Officer ("CEO") of ASYH to Chairman of ASYH following his cessation as CEO of ASYH with effect from 1 March 2019. With his cessation as the CEO of ASYH, the Board resolved to re-designate Mr. Aydinlar as a Non-Executive Director of IHH with effect from 1 March 2019. |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 6-4-2019 07:07 AM
|
显示全部楼层
Name | PULAU MEMUTIK VENTURES SDN BHD | Address | Level 33, Tower 2, Petronas Twin Towers
Kuala Lumpur City Centre
Kuala Lumpur
50088 Wilayah Persekutuan
Malaysia. | Company No. | 887202-X | Nationality/Country of incorporation | Malaysia | Descriptions (Class) | Ordinary shares |
Details of changesNo | Date of change | No of securities | Type of Transaction | Nature of Interest | | 1 | 19 Mar 2019 | 1,403,087,400 | Disposed | Direct Interest | Name of registered holder | Pulau Memutik Ventures Sdn Bhd | Address of registered holder | Level 33, Tower 2, Petronas Twin Towers, Kuala Lumpur City Centre, 50088 Kuala Lumpur | Description of "Others" Type of Transaction | |
Circumstances by reason of which change has occurred | Completion of Share Purchase Agreement dated 28 November 2018 between Pulau Memutik Ventures Sdn Bhd and Mitsui & Co., Ltd. on divestment of 1,403,087,400 shares in IHH Healthcare Berhad. | Nature of interest | Direct Interest | Direct (units) | 2,284,536,356 | Direct (%) | 26.052 | Indirect/deemed interest (units) | 0 | Indirect/deemed interest (%) | 0 | Total no of securities after change | 2,284,536,356 | Date of notice | 22 Mar 2019 | Date notice received by Listed Issuer | 22 Mar 2019 |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 6-4-2019 07:07 AM
|
显示全部楼层
Name | MITSUI & CO., LTD. | Address | 1-3, Marunouchi 1-Chome
Chiyoda-ku
Tokyo
100-8631
Japan. | Company No. | 1010001008767 | Nationality/Country of incorporation | Japan | Descriptions (Class) | Ordinary shares |
Details of changesNo | Date of change | No of securities | Type of Transaction | Nature of Interest | | 1 | 19 Mar 2019 | 1,403,087,400 | Acquired | Direct Interest | Name of registered holder | Mitsui & Co., Ltd. | Address of registered holder | 1-3, Marunouchi 1-Chome, Chiyoda-ku, Tokyo 100-8631, Japan | Description of "Others" Type of Transaction | |
Circumstances by reason of which change has occurred | Acquisition of shares pursuant to the Share Purchase Agreement dated 28 November 2018 with Pulau Memutik Ventures Sdn Bhd ("PMV"), pursuant to which Mitsui & Co., Ltd. has agreed, subject to the fulfillment of conditions precedent, to acquire shares in IHH Healthcare Berhad ("IHH"), representing 16% of the share capital of IHH from PMV. | Nature of interest | Direct Interest | Direct (units) | 2,888,487,400 | Direct (%) | 32.939 | Indirect/deemed interest (units) | 0 | Indirect/deemed interest (%) | 0 | Total no of securities after change | 2,888,487,400 | Date of notice | 22 Mar 2019 | Date notice received by Listed Issuer | 22 Mar 2019 |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 10-4-2019 05:33 AM
|
显示全部楼层
EX-date | 26 Jun 2019 | Entitlement date | 28 Jun 2019 | Entitlement time | 05:00 PM | Entitlement subject | First and Final Dividend | Entitlement description | A first and final single tier cash dividend of 3 sen per ordinary share for the financial year ended 31 December 2018 | Period of interest payment | to | Financial Year End | 31 Dec 2018 | Share transfer book & register of members will be | to closed from (both dates inclusive) for the purpose of determining the entitlement | Registrar or Service Provider name, address, telephone no | BOARDROOM SHARE REGISTRARS SDN BHDLevel 6, Symphony HousePusat Dagangan Dana 1Jalan PJU 1A/4647301 Petaling JayaSelangor Darul EhsanTel:03-7849 0777Fax:03-7841 8151 / 8152 | Payment date | 18 Jul 2019 | a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers | 28 Jun 2019 | b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit |
| | c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange. | Number of new shares/securities issued (units) (If applicable) |
| | Entitlement indicator | Currency | Currency | Malaysian Ringgit (MYR) | Entitlement in Currency | 0.03 |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 11-4-2019 06:43 AM
|
显示全部楼层
Type | Announcement | Subject | AUDIT REPORT - MODIFIED OPINION / MATERIAL UNCERTAINTY RELATED TO GOING CONCERN
QUALIFIED OPINION | Description | Qualified Opinion on the Audited Financial Statements for the financial year ended 31 December 2018 | |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 2-6-2019 10:20 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 30-6-2019 08:18 AM
|
显示全部楼层
本帖最后由 icy97 于 5-7-2019 08:32 AM 编辑
Date of change | 31 Dec 2019 | Name | DR TAN SEE LENG | Age | 54 | Gender | Male | Nationality | Singapore | Designation | Managing Director | Directorate | Executive | Type of change | Others | Description | Dr Tan See Leng ("Dr Tan") shall cease as the Managing Director and Chief Executive Officer of IHH Healthcare Berhad ("IHH") at the expiry of his contract of employment on 31 December 2019. |
QualificationsNo | Qualifications | Major/Field of Study | Institute/University | Additional Information | | 1 | Professional Qualification | Fellow | College of Family Physicians, Singapore | | | 2 | Professional Qualification | Fellow | Academy of Medicine, Singapore | | | 3 | Masters | Business Administration | University of Chicago Booth School of Business | | | 4 | Masters | Medicine (Family Medicine) | National University of Singapore | | | 5 | Degree | Bachelor of Medicine and Bachelor of Surgery (MBBS) | National University of Singapore | |
Working experience and occupation | Dr Tan was appointed the Managing Director and Chief Executive Officer ("CEO") of IHH in January 2014 after serving as an Executive Director on the IHH Board for 2 years. Dr Tan is currently the Group CEO and Managing Director of Parkway Pantai Limited, a position he assumed in 2011. He also serves on the Boards of IHH subsidiaries, namely Parkway Pantai Limited, Fortis Healthcare Limited, SRL Limited and Acibadem Saglik Yatirimlari Holding A.S. ("ASYH") Group and on a Board Committee of ASYH. He also serves on the Advisory Board of Lee Kong Chian School of Business at Singapore Management University and on the Board of Parkway Trust Management Limited ("PTM"), an indirect wholly-owned subsidiary of IHH. PTM manages Parkway Life Real Estate Investment Trust, which is listed on the Singapore Exchange Securities Trading Limited.Prior to this, Dr Tan was the CEO of Parkway Holdings Limited from April 2010, a position he rose to fairly quickly after he joined Parkway in 2004 as Chief Operating Officer of Mount Elizabeth Hospital. As a young entrepreneur, Dr Tan founded a private primary healthcare group at the age of 27 and subsequently developed it into the second largest primary healthcare group in Singapore before successfully selling the company to a leading global health-plan and insurance provider.With over 27 years of healthcare experience, Dr Tan has served as an active member of various medical committees, such as Singapore Ministry of Health's MediShield Life Review Committee. He has been reappointed Adjunct Assistant Professor of Duke-NUS Graduate Medical School Singapore, Office of Education, for the period until 2019. | Family relationship with any director and/or major shareholder of the listed issuer | Nil | Any conflict of interests that he/she has with the listed issuer | Nil | Details of any interest in the securities of the listed issuer or its subsidiaries | Dr Tan's interest as at 27 May 2019 is as follows: Direct interest in IHH: 1) 2,863,300 ordinary shares 2) 1,308,000 Long Term Incentive Plan units 3) 20,661,000 Enterprise Option Scheme optionsDirect interest in a subsidiary:Parkway Pantai Limited [USD500 million 4.25% Senior Perpetual Securities] - Value of securities held: USD3,000,000 |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 30-6-2019 08:18 AM
|
显示全部楼层
本帖最后由 icy97 于 5-7-2019 08:32 AM 编辑
Date of change | 01 Jul 2019 | Name | DR KELVIN LOH CHI-KEON | Age | 45 | Gender | Male | Nationality | Singapore | Designation | Executive Director | Directorate | Executive | Type of change | Appointment |
QualificationsNo | Qualifications | Major/Field of Study | Institute/University | Additional Information | | 1 | Masters | Business Administration | National University of Singapore Business School | | | 2 | Degree | Bachelor of Medicine and Bachelor of Surgery | National University of Singapore | |
Working experience and occupation | Dr Kelvin Loh Chi-Keon ("Dr Kelvin Loh") joins IHH Healthcare Berhad ("IHH") from Columbia Asia Group where he was Chief Executive Officer ("CEO"). Dr Kelvin Loh started his career as a practicing physician before serving for 10 years in the public sector in Singapore, in areas such as clinical services development, hospital planning and hospital operations. Dr Kelvin Loh previously joined the IHH Group in 2008, and between 2008 and 2017 held a number of senior management roles, before taking over as CEO for the Singapore Operations Division, covering among other services, the 4 multi-specialty tertiary hospitals - Mount Elizabeth, Mount Elizabeth Novena, Gleneagles and Parkway East.Dr Kelvin Loh moved to Columbia Asia Group as CEO in 2017 where he was responsible for overseeing Columbia Asia Group's 28 hospitals across 4 countries in Asia including Malaysia and India. Dr Kelvin Loh is a senior healthcare executive with strong track record of delivery. He has extensive experience in leading large healthcare businesses, building relationships with stakeholders, managing hospital operations, financial management and developing people. He is also deeply familiar with the healthcare operating context in diverse countries across Asia. | Directorships in public companies and listed issuers (if any) | Nil | Family relationship with any director and/or major shareholder of the listed issuer | Nil | Any conflict of interests that he/she has with the listed issuer | Nil | Details of any interest in the securities of the listed issuer or its subsidiaries | Dr Kelvin Loh's interest as at 27 May 2019 is as follows: Direct interest in a subsidiary:Parkway Life Real Estate Investment Trust - 120,000 units |
| Remarks : | | Dr Kelvin Loh will assume the position of Managing Director and Chief Executive Officer of IHH with effect from 1 January 2020, to succeed Dr Tan See Leng upon the completion of his contract period on 31 December 2019. Prior to the effective date of his appointment on 1 January 2020, Dr Kelvin Loh will be joining the IHH Group as CEO (designate) and Executive Director to undertake a transitionary process from 1 July 2019 onwards. |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 5-7-2019 08:32 AM
|
显示全部楼层
本帖最后由 icy97 于 6-7-2019 08:33 AM 编辑
SUMMARY OF KEY FINANCIAL INFORMATION
31 Mar 2019 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 31 Mar 2019 | 31 Mar 2018 | 31 Mar 2019 | 31 Mar 2018 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 3,642,687 | 2,854,953 | 3,642,687 | 2,854,953 | | 2 | Profit/(loss) before tax | 187,086 | 89,878 | 187,086 | 89,878 | | 3 | Profit/(loss) for the period | -8,942 | 29,151 | -8,942 | 29,151 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 89,510 | 57,235 | 89,510 | 57,235 | | 5 | Basic earnings/(loss) per share (Subunit) | 0.78 | 0.44 | 0.78 | 0.44 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 2.5000 | 2.5100
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 14-7-2019 07:32 AM
|
显示全部楼层
Particulars of substantial Securities HolderName | MITSUI & CO., LTD. | Address | 1-3, Marunouchi 1-Chome,
Chiyoda-ku,
Tokyo
100-8631
Japan. | Company No. | 1010001008767 | Nationality/Country of incorporation | Japan | Descriptions (Class) | Ordinary shares |
Details of changesNo | Date of change | No of securities | Type of Transaction | Nature of Interest | | 1 | 18 Jun 2019 | 2,888,487,400 | Transferred | Direct Interest | Name of registered holder | Mitsui & Co., Ltd. | Address of registered holder | 1-3, Marunouchi 1-Chome, Chiyoda-ku Tokyo 100-8631, Japan | Description of "Others" Type of Transaction | | | 2 | 18 Jun 2019 | 2,888,487,400 | Transferred | Indirect Interest | Name of registered holder | MBK Healthcare Management Pte Ltd | Address of registered holder | 8 Robinson Road, #14-00, ASO Building, Singapore 048544 | Description of "Others" Type of Transaction | |
Circumstances by reason of which change has occurred | Change from direct to indirect holding of shares due to the transfer of 2,888,487,400 shares in IHH Healthcare Berhad from Mitsui & Co., Ltd. to MBK Healthcare Management Pte Ltd, wholly-owned subsidiary of Mitsui & Co., Ltd. | Nature of interest | Direct and Indirect Interest | Direct (units) | 0 | Direct (%) | 0 | Indirect/deemed interest (units) | 2,888,487,400 | Indirect/deemed interest (%) | 32.921 | Total no of securities after change | 2,888,487,400 | Date of notice | 18 Jun 2019 | Date notice received by Listed Issuer | 18 Jun 2019 |
|
|
|
|
|
|
|
|
|
|
| |
 本周最热论坛帖子
|
2183 
259
